Platelet count and the risk for thrombosis and death in the elderly

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 3, 2009, Pages 399-405

  van der Bom, Johanna G ^a   Heckbert, S R ^b,c,d   Lumley, T ^b,c   Holmes, C E ^e   Cushman, M ^e   Folsom, A R ^f   Rosendaal, F R ^a   Psaty, B M ^b,c,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Elderly; Mortality; Platelet count; Thrombosis

Indexed keywords

AGED; ARTICLE; CANCER MORTALITY; CEREBROVASCULAR ACCIDENT; COMMUNITY LIVING; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOSIS; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET COUNT; RISK; STROKE; SURVIVAL ANALYSIS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 59849099066     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03267.x     Document Type: Article

References (27)

1. Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, Chesterman CN, Donald JA. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost 2000; 83: 480-4.
2. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56: 168-72.
3. Hehlmann R, Jahn M, Baumann B, Kopcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988; 61: 2487-96.
4. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-56.
5. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1991; 1: 263-76.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97.
7. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995; 5: 278-85.
8. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.
9. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-9.
10. Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, Gibson CM. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006; 98: 1-5.
11. Eikelboom JW, Anand SS, Mehta SR, Weitz JI, Yi C, Yusuf S. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. Circulation 2001; 103: 643-50.
12. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count. J Intern Med 1999; 245: 295-300.
13. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, Cushman M. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: The Cardiovascular Health Study. J Thromb Haemost 2007; 5: 1128-35.
14. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
15. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100: 736-42.
16. Meade TW, Cooper JA, Miller GJ. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 1997; 78: 926-9.
17. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, Macfarlane P, Packard C. Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 553-8.
18. Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in patients with colorectal cancer - a preliminary study. Thromb Haemost 1998; 79: 916-8.
19. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-7.
20. Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998; 70: 210-4.
21. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-91.
22. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3: 425-30.
23. Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: Does it offer a chance of better cancer progression control? Semin Thromb Hemost 2007; 33: 712-21.
24. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995; 74: 282-90.
25. Pearlstein E, Ambrogio C, Karpatkin S. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. Cancer Res 1984; 44: 3884-7.
26. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995; 98: 551-8.
27. Suzuki A, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imura H. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1992; 80: 2052-9.